Nisha Marathe
Direktor/Vorstandsmitglied bei Soteria Biotherapeutics, Inc.
Aktive Positionen von Nisha Marathe
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Private Equity Investor | 01.01.2018 | - |
| Private-Equity-Analyst | 01.03.2016 | 01.01.2018 | |
Soteria Biotherapeutics, Inc.
 Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Nisha Marathe
Statistik
International
| Schweiz | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Private Equity Analyst | 1 |
| Private Equity Investor | 1 |
| Director/Board Member | 1 |
Sektoral
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
Soteria Biotherapeutics, Inc.
Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Nisha Marathe
- Erfahrung
